Current price about 8% below the Citi target price and we all know how negative they have been with the articles.
If sales revenue was going to that slow over the first 4 months, why are we already seeing on the shelves a2m IF with a MFD in mid to late September?
Seems that supply chains, efficiencies and supply is improving and supply is increasing.
GLTAH and DYOR
- Forums
- ASX - By Stock
- A2M
- A2 Analyst Valuations
A2 Analyst Valuations, page-20
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
|
|||||
Last
$6.82 |
Change
-0.030(0.44%) |
Mkt cap ! $4.937B |
Open | High | Low | Value | Volume |
$6.88 | $6.90 | $6.81 | $1.426M | 208.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
23 | 11797 | $6.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.82 | 2386 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 12640 | 6.810 |
19 | 21081 | 6.800 |
14 | 39148 | 6.790 |
6 | 6890 | 6.780 |
8 | 90841 | 6.770 |
Price($) | Vol. | No. |
---|---|---|
6.820 | 2618 | 7 |
6.830 | 16939 | 13 |
6.840 | 22981 | 12 |
6.850 | 28027 | 13 |
6.860 | 31275 | 11 |
Last trade - 11.05am 16/07/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online